Prior information notice
This notice is for prior information only
Section I: Contracting
authority
I.1) Name and addresses
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
UK
Contact person: NHS England
E-mail: england.commercialqueries@nhs.net
NUTS: UKI
Internet address(es)
Main address: https://www.england.nhs.uk/
Address of the buyer profile: https://www.england.nhs.uk/
I.3) Communication
Additional information can be obtained from the abovementioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
https://atamis-1928.my.site.com/s/Welcome
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Preliminary Market Engagement Notice: Targeted Prostate Cancer Screening Programme - PSA Testing, MRI Reporting and BRCA Digital Decision Resource
Reference number: C463159
II.1.2) Main CPV code
85145000
II.1.3) Type of contract
Services
II.1.4) Short description
NHS England is undertaking early market engagement to inform three separate requirements within the Targeted Prostate Cancer Screening Programme.
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
85100000
85150000
85148000
85145000
II.2.3) Place of performance
NUTS code:
UK
II.2.4) Description of the procurement
Preliminary Market Engagement / Early Market Engagement<br/><br/>NHS England is undertaking preliminary market engagement to inform three separate but connected requirements within the Targeted Prostate Cancer Screening Programme.<br/><br/>The proposed workstreams are:<br/><br/>1. PSA laboratory processing and pathway support;<br/>2. prostate MRI reporting;<br/>3. BRCA digital decision resource / website development and evaluation.<br/><br/>The programme is being developed to support targeted prostate cancer screening for men at increased risk, including men with a known pathogenic or likely pathogenic BRCA2 variant. The purpose of this engagement is to understand market capability, potential delivery models, mobilisation requirements, key risks, pricing assumptions, digital and information governance considerations, pathway interfaces and route-to-market options.<br/><br/>The workstreams involve different capabilities and provider markets. NHS England may procure the requirements separately, and different procurement routes may apply to different workstreams. NHS England is currently assessing the most appropriate route to market for each workstream. Subject to completion of the relevant approvals and assessments, Workstreams 1 and 2 are anticipated to be procured under the Provider Selection Regime where confirmed as being within scope of that regime. Workstream 3 is anticipated to be procured in accordance with the Procurement Act 2023.<br/><br/>This engagement is not a call for competition, does not commence a procurement process, and does not commit NHS England to any procurement, route to market, contract award or level of expenditure. Participation in this engagement is not required in order to participate in any future procurement process, and non-participation will not prevent participation in any future opportunity.<br/><br/>Suppliers may respond to one, two or all three workstreams, depending on their capability and interest.<br/><br/>The Preliminary Market Engagement Notice uses 85100000-0 Health services as the main CPV code because the engagement relates to a targeted screening programme and includes two clinical/diagnostic workstreams. Additional CPV codes have been included to reflect the specific workstreams: PSA laboratory processing and medical analysis, prostate MRI reporting, and digital decision resource / website development. The use of multiple CPV codes reflects the fact that this is one combined market engagement exercise only; the workstreams may be procured separately and may follow different procurement routes following Commercial review.
II.3) Estimated date of publication of contract notice:
07/12/2026
Section IV: Procedure
IV.1) Description
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section VI: Complementary information
VI.3) Additional information
The Preliminary Market Engagement Notice uses 85100000-0 Health services as the main CPV code as the engagement relates to a targeted screening programme and includes two clinical/diagnostic workstreams. Additional CPV codes included to reflect the specific workstreams: PSA laboratory processing & medical analysis, prostate MRI reporting, & digital decision resource/website development. The use of multiple CPV codes reflects the fact that this is one combined market engagement.<br/><br/>Please note the following CPV codes are being utilised as well for the early engagement (but are not PSR related):<br/><br/>World wide web (www) site design services<br/>72413000<br/>Internet and intranet software development services<br/>72212220<br/>IT services: consulting, software development, Internet and support<br/>72000000<br/><br/>A separate, relevant PA23 early engagement notice has been released with all CPV codes as well.
VI.5) Date of dispatch of this notice
05/08/2026